6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 7,500
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Kevin Ronald Sayer | Exec. Chairman, CEO & Pres | 2.22M | N/D | 1958 |
Mr. Jereme M. Sylvain | Exec. VP, CFO & Chief Accounting Officer | 841.14k | N/D | 1980 |
Mr. Jacob Steven Leach | Exec. VP & COO | 994.13k | N/D | 1978 |
Mr. Girish Naganathan | Exec. VP & CTO | 423.92k | N/D | 1977 |
Mr. Michael Jon Brown | Exec. VP & Chief Legal Officer | 954.46k | N/D | 1970 |
Mr. Shelly Ramasamy Selvaraj | Sr. VP & Chief Information Officer | N/D | N/D | 1959 |
Mr. Sean Christensen | Director of Corp. Affairs & Head of Investor Relations | N/D | N/D | N/D |
Mr. Matthew Dolan | Exec. VP of Strategy, Corp. Devel. & Dexcom Labs | N/D | N/D | 1981 |
Ms. Sadie M. Stern | Exec. VP & Chief HR Officer | N/D | N/D | 1975 |
Mr. Andrew K. Balo | Exec. VP of Global Medical Affairs, Access & Evidence | N/D | N/D | 1948 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
La calificación ISS Governance QuickScore de DexCom, Inc. a partir del 1 de mayo de 2023 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 6; Compensación: 7.